TrialPath
Recruiting

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

NCT04793919 · Associazione Italiana Ematologia Oncologia Pediatrica
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
Acute promyelocytic leukemia (APL) in children has become a highly curable disease with the combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy with an overall remission rates equal to or higher than 98% and cure rates now exceeding 80% 1-9. Based on data coming from adults indicating that at least standard-risk APL patients may be cured without chemotherapy (i.e., with a treatment combining arsenic trioxide (ATO) and ATRA only) 10-12, this ICC APL 02 study was designed with the aim of validating the efficacy of a treatment combining: * ATO and ATRA in newly diagnosed APL standard-risk (SR) children and adolescents and * ATO, ATRA and gemtuzumab ozogamicin (GO) in newly diagnosed APL high-risk (HR) children and adolescents. Following one induction course of treatment combining ATO and ATRA +/- GO depending on risk stratification, patients will receive 4 ATO/ATRA based consolidation blocks. This is the first pediatric trial delivering a non-chemotherapy-based treatment for children with APL, being the whole treatment based on the use of ATRA, ATO (and GO in HR patients). The aim of the study is to demonstrate at least an equivalent efficacy and safety of this treatment not containing cytostatic agents compared to the standard protocols combining ATRA and chemotherapy (i.e. ICC APL Study 01). The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age. This will be an international study, comprising the most important pediatric European groups, expecting to recruit 46 and 43 patients in SR and HR arms, respectively, in 3 years. The duration of study recruitment will be 36 months with a minimum follow-up per patient of 2 years. The evaluation of morphological CR will be carried out after induction therapy, prior to the first block of consolidation therapy. MRD results after induction will not have an impact on subsequent therapy. By contrast, MRD results after the third consolidation course will influence the subsequent treatment, MRD-positive patients being eligible to rescue treatment, including hematopoietic stem cell transplantation (HSCT). BM aspirates will be repeated after the end of therapy, and 3 months, 6 months, 9 months and 12 months after treatment discontinuation. This is a collaborative international study in APL in children and adolescents aimed at providing information about procedures for the entry, treatment and follow-up of pediatric patients with APL. It is not intended that this document be used as an aide-memoir or guide for the treatment of other patients. Every care has been taken in its drafting, but corrections and amendments may be necessary. Before entering patients into the study, clinicians must ensure that the study has received clearance from their Local Research Ethics Committee and any other necessary body.
Eligibility criteria
Inclusion Criteria: * Newly diagnosed APL confirmed by the presence of PML/RARα fusion gene * Age \<18 years * Written informed consent by parents or legal guardians Exclusion Criteria: * Patients with a clinical diagnosis of APL but subsequently found to lack PML/RARα rearrangement should be withdrawn from the study and treated on an alternative protocol * Significant liver dysfunction (bilirubin serum levels \>3 mg/dL, ALT/AST serum levels greater than 5 times the normal values) * Creatinine serum levels \>2 times the normal value for age * Significant arrhythmias, EKG abnormalities (\*see below), other cardiac contraindications (L-FEV \<50% or LV-FS \<28%) * Neuropathy * Concurrent active malignancy * Uncontrolled life-threatening infections * Pregnant or lactating female * Patients who had received alternative therapy (APL not initially suspected; ATRA and/or ATO not available
Study design
Enrollment target: 89 participants
Allocation: non_randomized
Masking: none
Age groups: child, adult
Timeline
Starts: 2019-10-09
Estimated completion: 2027-10-10
Last updated: 2024-04-15
Interventions
Drug: MylotargDrug: Arsenic TrioxideDrug: All-trans retinoic acid
Primary outcomes
  • • Event Free Survival (EFS) probability (3 years)
Sponsor
Associazione Italiana Ematologia Oncologia Pediatrica · other
Contacts & investigators
ContactAIEOP · contact · studiclinici@aieop.org · 0039 051 2144667
InvestigatorFanco Locatelli, Prof · principal_investigator, Dept. of Pediatric Hematology Oncology - Bambino Gesù Children's Hospital Rome
All locations (31)
Hôpital Universitaire des Enfants Reine Fabiola (Huderf)Not Yet Recruiting
Brussels, Belgium
University Hospital MotolNot Yet Recruiting
Prague, Czechia
Pediatrics and Adolescent Medicine Aarhus University HospitalNot Yet Recruiting
Aarhus N, Denmark
CHU de Bordeaux - Hôpital des EnfantsRecruiting
Bordeaux, France
Universitätsklinikum Essen (AöR) Zentrum für Kinder-und Jugendmedizin Klinik für Kinderheilkunde IIINot Yet Recruiting
Essen, Germany
Our Lady's Children's Hospital CrumlinNot Yet Recruiting
Dublin, Ireland
Rappaport Children'S Hospital, Rambam Health Care CampusNot Yet Recruiting
Haifa, Israel
Ospedale "Casa Sollievo della Sofferenza" - UO Oncoematologia PediatricaRecruiting
San Giovanni Rotondo, Foggia, Italy
AOU Policlinico Dipartimento di PediatriaNot Yet Recruiting
Bari, Italy
Ospedale Papa Giovanni XXIII - USS Oncoematologia PediatricaNot Yet Recruiting
Bergamo, Italy
AOU Policlinico Sant'Orsola-Malpighi - Oncologia ed Ematologia PediatricaRecruiting
Bologna, Italy
Ospedale Pediatrico Microcitemico "A.Cau", Az.Ospedaliera Brotzu - SC Oncoematologia Ped. e Patologia della coagulazioneRecruiting
Cagliari, Italy
AOU Policlinico Vittorio Emanuele - UOC Ematologia ed Oncologia Pediatrica con TNORecruiting
Catania, Italy
A.O. Universitaria Meyer - DAI Oncoematologia PediatricaNot Yet Recruiting
Florence, Italy
IRCCS Istituto Gannina Gaslini - Dipartimento di OncoematologiaRecruiting
Genova, Italy
Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM) - Ospedale San GerardoRecruiting
Monza, Italy
AORN Santobono-PausiliponRecruiting
Naples, Italy
Univerità degli Studi della Campania- Luigi Vanvitelli - Sevizio di Oncologia PediatricaRecruiting
Naples, Italy
Azienda Ospedaliera di Padova - Oncoematologia PediatricaNot Yet Recruiting
Padova, Italy
ARNAS Civico di Cristina e Benfratelli - UOC Oncoematologia PediatricaNot Yet Recruiting
Palermo, Italy
Fondazione IRCCS Policlinico San Matteo - Oncoematologia PediatricaRecruiting
Pavia, Italy
Ospedale santa Chiara - AOU Pisana, UO Oncoematologia PediatricaNot Yet Recruiting
Pisa, Italy
Policlinico Umberto I Università "LA Sapienza" - Dip. Biotecnologie cellulari ed ematologia UOS Ematologia PediatricaNot Yet Recruiting
Roma, Italy
Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica - Ospedale Pediatrico "Bambino Gesù"Recruiting
Roma, Italy
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina MargheritaRecruiting
Torino, Italy
VU medisch centrumNot Yet Recruiting
Amsterdam, Netherlands
Centro Hospitalar Universitário de Coimbra - Hospital Pediátrico de CoimbraNot Yet Recruiting
Coimbra, Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil, EPENot Yet Recruiting
Lisbon, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E.Not Yet Recruiting
Porto, Portugal
Valencia University Medical School University Hospital La FeNot Yet Recruiting
Valencia, Spain
Childrens hematology and oncology Uppsala UniversityNot Yet Recruiting
Uppsala, Sweden